Morning session - Is cognitive dysfunction in MDD a distinct entity?
Afternoon session- Takeda's vortioxetine for the treatment of cognitive dysfunction in MDD
Read MoreMorning session - Is cognitive dysfunction in MDD a distinct entity?
Afternoon session- Takeda's vortioxetine for the treatment of cognitive dysfunction in MDD
Read MoreMorning session - Is cognitive dysfunction in MDD a distinct entity?
Afternoon session- Takeda's vortioxetine for the treatment of cognitive dysfunction in MDD
Read MoreMorning session - Is cognitive dysfunction in MDD a distinct entity?
Afternoon session- Takeda's vortioxetine for the treatment of cognitive dysfunction in MDD
Read MoreDiscussion of the results from two cardiovascular outcomes trials for two DPP4 inhibitor's: AstraZeneca's saxagliptin and Takeda's alogliptin
Read MoreDiscussion of the results from two cardiovascular outcomes trials for two DPP4 inhibitor's: AstraZeneca's saxagliptin and Takeda's alogliptin
Read MoreDiscussion of the results from two cardiovascular outcomes trials for two DPP4 inhibitor's: AstraZeneca's saxagliptin and Takeda's alogliptin
Read MoreDiscussion of the results from two cardiovascular outcomes trials for two DPP4 inhibitor's: AstraZeneca's saxagliptin and Takeda's alogliptin
Read More